{"id":"https://openalex.org/W2419060740","doi":null,"title":"[CYP2C9 and VKORC1 gene polymorphism and acenocoumarol anticoagulant activity in Russian patients at high risk of thromboembolic complications].","display_name":"[CYP2C9 and VKORC1 gene polymorphism and acenocoumarol anticoagulant activity in Russian patients at high risk of thromboembolic complications].","publication_year":2011,"publication_date":"2011-01-01","ids":{"openalex":"https://openalex.org/W2419060740","mag":"2419060740","pmid":"https://pubmed.ncbi.nlm.nih.gov/21544933"},"language":"ru","primary_location":{"id":"pmid:21544933","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21544933","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Vestnik Rossiiskoi akademii meditsinskikh nauk","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5113720690","display_name":"D A Sychev","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D A Sychev","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021591644","display_name":"Ignat'ev","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"I V Ignat'ev","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053243615","display_name":"\u041a\u0440\u043e\u043f\u0430\u0447\u0435\u0432\u0430 \u0415\u043a\u0430\u0442\u0435\u0440\u0438\u043d\u0430 \u0421\u0442\u0430\u043d\u0438\u0441\u043b\u0430\u0432\u043e\u0432\u043d\u0430","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E S Kropacheva","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027075829","display_name":"Emel'ianov Nv","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"N V Emel'ianov","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006621446","display_name":"\u0412. \u0412. \u041c\u0438\u043b\u043e\u0432\u0430\u043d\u043e\u0432\u0430","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"V V Milovanova","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Iu A Naumova","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Iu A Naumova","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023143326","display_name":"\u0410 \u0412 \u041a\u043e\u0441\u0441\u043e\u0432\u0441\u043a\u0430\u044f","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A V Kosovskaia","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053765548","display_name":"O B Dobrovol'ski\u012d","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"O B Dobrovol'ski\u012d","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047755842","display_name":"\u0410. \u0418. \u0422\u0430\u0448\u0435\u043d\u043e\u0432\u0430","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A I Tashenova","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066364508","display_name":"E P Panchenko","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E P Panchenko","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5080038233","display_name":"Kukes Vg","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"V G Kukes","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.4347,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.62130178,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":null,"issue":"3","first_page":"7","last_page":"10"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10881","display_name":"Blood Coagulation and Thrombosis Mechanisms","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13984","display_name":"Nutrition, Genetics, and Disease","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acenocoumarol","display_name":"acenocoumarol","score":0.9399999976158142},{"id":"https://openalex.org/keywords/cyp2c9-polymorphism","display_name":"CYP2C9 polymorphism","score":0.9390000104904175},{"id":"https://openalex.org/keywords/vkorc1-polymorphism","display_name":"VKORC1 polymorphism","score":0.9700000286102295},{"id":"https://openalex.org/keywords/anticoagulant-response","display_name":"anticoagulant response","score":0.6269999742507935},{"id":"https://openalex.org/keywords/international-normalized-ratio","display_name":"international normalized ratio","score":0.6520000100135803},{"id":"https://openalex.org/keywords/hemorrhage","display_name":"hemorrhage","score":0.6549999713897705},{"id":"https://openalex.org/keywords/thromboembolic-risk","display_name":"thromboembolic risk","score":0.8899999856948853},{"id":"https://openalex.org/keywords/pharmacogenetics","display_name":"pharmacogenetics","score":0.7630000114440918},{"id":"https://openalex.org/keywords/russian-patients","display_name":"Russian patients","score":0.671999990940094}],"concepts":[{"id":"https://openalex.org/C2781344064","wikidata":"https://www.wikidata.org/wiki/Q304088","display_name":"Acenocoumarol","level":4,"score":0.9763306379318237},{"id":"https://openalex.org/C2776318485","wikidata":"https://www.wikidata.org/wiki/Q18045930","display_name":"VKORC1","level":5,"score":0.9522331357002258},{"id":"https://openalex.org/C3946865","wikidata":"https://www.wikidata.org/wiki/Q5014962","display_name":"CYP2C9","level":4,"score":0.944483757019043},{"id":"https://openalex.org/C31467283","wikidata":"https://www.wikidata.org/wiki/Q912147","display_name":"Genotyping","level":4,"score":0.7691094875335693},{"id":"https://openalex.org/C135763542","wikidata":"https://www.wikidata.org/wiki/Q106016","display_name":"Genotype","level":3,"score":0.6655733585357666},{"id":"https://openalex.org/C55775858","wikidata":"https://www.wikidata.org/wiki/Q1152227","display_name":"Pharmacogenetics","level":4,"score":0.5751553177833557},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5321981310844421},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5188730359077454},{"id":"https://openalex.org/C76252995","wikidata":"https://www.wikidata.org/wiki/Q3395645","display_name":"Gene polymorphism","level":4,"score":0.49644404649734497},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.46460360288619995},{"id":"https://openalex.org/C149737253","wikidata":"https://www.wikidata.org/wiki/Q3240252","display_name":"Polymorphism (computer science)","level":4,"score":0.4416605532169342},{"id":"https://openalex.org/C2778205648","wikidata":"https://www.wikidata.org/wiki/Q215118","display_name":"Anticoagulant","level":2,"score":0.441481351852417},{"id":"https://openalex.org/C180754005","wikidata":"https://www.wikidata.org/wiki/Q80726","display_name":"Allele","level":3,"score":0.4148046374320984},{"id":"https://openalex.org/C2776301958","wikidata":"https://www.wikidata.org/wiki/Q407431","display_name":"Warfarin","level":3,"score":0.3156638741493225},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.2589612603187561},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.22160178422927856},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.17228743433952332},{"id":"https://openalex.org/C2779161974","wikidata":"https://www.wikidata.org/wiki/Q815819","display_name":"Atrial fibrillation","level":2,"score":0.10044962167739868}],"mesh":[{"descriptor_ui":"D000074","descriptor_name":"Acenocoumarol","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000074","descriptor_name":"Acenocoumarol","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000925","descriptor_name":"Anticoagulants","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001189","descriptor_name":"Aryl Hydrocarbon Hydroxylases","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D001281","descriptor_name":"Atrial Fibrillation","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006899","descriptor_name":"Mixed Function Oxygenases","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011110","descriptor_name":"Polymorphism, Genetic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012426","descriptor_name":"Russia","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013923","descriptor_name":"Thromboembolism","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D013923","descriptor_name":"Thromboembolism","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D013923","descriptor_name":"Thromboembolism","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":false},{"descriptor_ui":"D015331","descriptor_name":"Cohort Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064417","descriptor_name":"Vitamin K Epoxide Reductases","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D065729","descriptor_name":"Cytochrome P-450 CYP2C9","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":1,"locations":[{"id":"pmid:21544933","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21544933","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Vestnik Rossiiskoi akademii meditsinskikh nauk","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2050079116","https://openalex.org/W2025461698","https://openalex.org/W2795930492","https://openalex.org/W1968597827","https://openalex.org/W2123752042","https://openalex.org/W2044209784","https://openalex.org/W2302824588","https://openalex.org/W2042238217","https://openalex.org/W2094797117","https://openalex.org/W2762811656"],"abstract_inverted_index":{"The":[0,115],"study":[1],"included":[2],"25":[3],"patients":[4,42,105],"at":[5],"high":[6],"risk":[7],"of":[8,12,23,26,30,54,67,72,82,104,121,125],"thromboembolic":[9],"complications.":[10],"All":[11,40],"them":[13],"were":[14],"treated":[15,112],"with":[16,79,113],"acenocoumarol":[17],"for":[18,95,117],"6":[19],"months":[20],"under":[21],"control":[22],"the":[24,41,52,60,64,68,73,80,98,107],"frequency":[25],"hemorrhage":[27],"and":[28,45,56,63,93,101,111,123],"episodes":[29,85],"severe":[31,83],"hypocoagulation":[32,84],"(a":[33],"more":[34],"than":[35],"3-fold":[36],"rise":[37],"in":[38,59,97],"INR).":[39],"underwent":[43],"CYP2C9":[44,61],"VKORC1":[46,74,96],"genotyping.":[47],"It":[48],"was":[49,76],"shown":[50],"that":[51],"presence":[53],"CYP2C9*2":[55],"CYP2C9*3":[57],"alleles":[58],"locus":[62],"AA":[65],"genotype":[66,109],"polymorphous":[69],"G-1639(3673)A":[70],"marker":[71],"gene":[75],"not":[77],"associated":[78],"development":[81],"(p":[86],"=":[87,91],"0.261--for":[88],"CYP2C9,":[89],"p":[90],"0.616":[92],"0.361":[94],"total":[99],"group":[100],"a":[102],"subgroup":[103],"having":[106],"CYP2C9*1/*1":[108],"respectively":[110],"acenocoumarol.":[114],"search":[116],"other":[118],"genetic":[119],"markers":[120],"efficacy":[122],"safety":[124],"this":[126],"drug":[127],"should":[128],"be":[129],"continued.":[130]},"counts_by_year":[{"year":2020,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}